Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308889 · ClinicalTrials.gov registry record · Early Phase 1
Pro-Resolving Mediators in Acute Inflammation in Humans
A Early Phase 1 study of Blister and Inflammation; Skin, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04308889 is a Early Phase 1 study of Blister and Inflammation; Skin that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04308889, a Early Phase 1 study of Blister and Inflammation; Skin, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.
Conditions Studied
Interventions
- OTHER Phlebotomy
- DRUG Lovaza
- OTHER Cantharone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2022-02-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308889
The ClinicalTrials.gov registry entry for NCT04308889 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Blister appearing as the primary indexed condition, and to 3 interventions - of which Phlebotomy is the first listed.
NCT04308889 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04308889 about?
NCT04308889 is a clinical study titled "Pro-Resolving Mediators in Acute Inflammation in Humans". The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on infl...
What is the current status of trial NCT04308889?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2018-07-02. Estimated completion is 2022-02-22.
What conditions does trial NCT04308889 study?
This clinical trial studies the following conditions: Blister, Inflammation; Skin, Resolution.
What interventions are being tested in trial NCT04308889?
The interventions under investigation include: Phlebotomy (OTHER), Lovaza (DRUG), Cantharone (OTHER).
Who is sponsoring clinical trial NCT04308889?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04308889 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blister
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.